Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-10

Clinical Trial Update: A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) [Phase 3]

View source ↗

Summary

Phase 3 trial results for ruxolitinib cream in pediatric atopic dermatitis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Opzelura (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2024-06-10